Related Experiment Video
Updated: Feb 8, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
Published on: March 17, 2020
17-(Allylamino)-17-Demethoxygeldanamycin Enhances Etoposide-Induced Cytotoxicity via the Downregulation of Xeroderma
Jyh-Cheng Chen1, Peng-Fang Ma2, Yuan-Cheng Lin2
1Department of Food Science, National Chiayi University, Chiayi, Taiwan.
Abstract:
Etoposide (VP16) is a topoisomerase II inhibitor and has been used for the treatment of non-small cell lung cancer (NSCLC). Xeroderma pigmentosum complementation group C (XPC) protein is a DNA damage recognition factor in nucleotide excision repair and involved in regulating NSCLC cell proliferation and viability. Heat shock protein 90 (Hsp90) is a ubiquitous molecular chaperone that is responsible for the stabilization and maturation of many oncogenic proteins. In this study, we report whether Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) enhanced etoposide-induced cytotoxicity in NSCLC cells through modulating the XPC expression. We found that etoposide increased XPC expression in an AKT activation manner in 2 squamous cell carcinoma H1703 and H520 cells. Knockdown of XPC using siRNA or inactivation of AKT by pharmacological inhibitor PI3K inhibitor (LY294002) enhanced the cytotoxic effects of etoposide. In contrast, enforced expression of XPC cDNA or AKT-CA (a constitutively active form of AKT) reduced the cytotoxicity and cell growth inhibition of etoposide. Hsp90 inhibitor 17-AAG enhanced cytotoxicity and cell growth inhibition of etoposide in NSCLC cells, which were associated with the downregulation of XPC expression and inactivation of AKT. Our findings suggested that the Hsp90 inhibition induced XPC downregulation involved in enhancing the etoposide-induced cytotoxicity in H1703 and H520 cells.
Insights
Heat shock protein 90 (Hsp90) inhibition enhances etoposide chemotherapy for non-small cell lung cancer (NSCLC) by reducing Xeroderma pigmentosum complementation group C (XPC) expression. This approach increases etoposide
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Etoposide (VP16) is a topoisomerase II inhibitor used in non-small cell lung cancer (NSCLC) treatment.
- Xeroderma pigmentosum complementation group C (XPC) protein plays a role in DNA repair and NSCLC cell regulation.
- Heat shock protein 90 (Hsp90) stabilizes oncogenic proteins, making it a therapeutic target.
Purpose of the Study:
- To investigate if Hsp90 inhibition enhances etoposide-induced cytotoxicity in NSCLC cells by modulating XPC expression.
- To explore the role of AKT signaling in etoposide's effect on XPC expression and cytotoxicity.
Main Methods:
- Utilized etoposide and Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NSCLC cell lines (H1703, H520).
- Employed siRNA for XPC knockdown and PI3K inhibitor (LY294002) to inactivate AKT.
- Used enforced expression of XPC cDNA and constitutively active AKT (AKT-CA) to assess their effects.
Main Results:
- Etoposide increased XPC expression via AKT activation in NSCLC cells.
- XPC knockdown or AKT inactivation potentiated etoposide's cytotoxic effects.
- Enforced XPC or AKT expression reduced etoposide's cytotoxicity and growth inhibition.
- 17-AAG enhanced etoposide's cytotoxicity by downregulating XPC and inactivating AKT.
Conclusions:
- Hsp90 inhibition, through XPC downregulation, enhances etoposide-induced cytotoxicity in NSCLC cells.
- The AKT signaling pathway is implicated in the regulation of XPC by etoposide.
- Targeting Hsp90 in combination with etoposide may represent a viable therapeutic strategy for NSCLC.
Related Concept Videos
Cell Specific Gene Expression
Cell Specific Gene Expression
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

